Ketoconazole shampoo: hypersensitivity identified as an important risk

The risk management plan for Dermazol, a ketoconazole shampoo, describes important safety risks and measures to minimise them. The supplied abstract outlines the plan’s main provisions on identified risks, information gaps and ongoing pharmacovigilance. This is a description of a risk management plan, rather than the results of an individual clinical study.

Risks and information gaps

Hypersensitivity reactions are listed as an important identified risk. Missing information on safety in children, pregnant women and breastfeeding women is also noted. The abstract does not report the frequency, severity or clinical manifestations of hypersensitivity reactions.

Risk minimisation and ongoing monitoring

The plan includes routine risk minimisation activities and ongoing pharmacovigilance to collect and analyse adverse reaction data. The specific components of these activities are not detailed in the abstract.

No additional post-registration studies are planned: according to the abstract, the safety information is consistent with existing data. For practice, the key considerations remain the risk of hypersensitivity and the stated gaps in safety information.